Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Brief Summary: To assess a new drug, BAY94-8862, given orally at different doses, to evaluate whether it was safe and can help the well-being of patients with worsening chronic heart failure and either type II diabetes with or without chronic kidney disease or kidney disease alone. These treatment doses were compared to eplerenone, another marketed drug approved to treat heart failure.


Options:
A: Arm Label: Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eplerenone | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Eplerenone; Assigned to Arm(s): Treatment
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 4; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 5; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Arm 6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 5 | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Arm 6
C: Arm Label: Finerenone(BAY94-8862)[2.5mg] + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862), Drug: Placebo | Arm Label: Finerenone (BAY94-8862)[5mg] + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862), Drug: Placebo | Arm Label: Finerenone (BAY94-8862)[7.5mg] + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862), Drug: Placebo | Arm Label: Finerenone (BAY94-8862)[10mg] + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862), Drug: Placebo | Arm Label: Finerenone (BAY94-8862)[15mg] + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862), Drug: Placebo | Arm Label: Eplerenone [25 mg] + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Inspra (eplerenone) | Intervention Type: DRUG; Name: Finerenone (BAY94-8862); Assigned to Arm(s): Finerenone (BAY94-8862)[10mg] + Placebo, Finerenone (BAY94-8862)[15mg] + Placebo, Finerenone (BAY94-8862)[5mg] + Placebo, Finerenone (BAY94-8862)[7.5mg] + Placebo, Finerenone(BAY94-8862)[2.5mg] + Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Eplerenone [25 mg] + Placebo, Finerenone (BAY94-8862)[10mg] + Placebo, Finerenone (BAY94-8862)[15mg] + Placebo, Finerenone (BAY94-8862)[5mg] + Placebo, Finerenone (BAY94-8862)[7.5mg] + Placebo, Finerenone(BAY94-8862)[2.5mg] + Placebo | Intervention Type: DRUG; Name: Inspra (eplerenone); Assigned to Arm(s): Eplerenone [25 mg] + Placebo
D: Arm Label: ACE/ARB; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Spironolactone/ARB; Type: ACTIVE_COMPARATOR; Interventions: Drug: spironolacone 25 mg tablets added to losartan | Intervention Type: DRUG; Name: spironolacone 25 mg tablets added to losartan; Assigned to Arm(s): Spironolactone/ARB

Answer: C